Gilead Sciences’ (GILD) Buy Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their buy rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report released on Tuesday, May 7th, Stock Target Advisor reports. The brokerage currently has a $87.00 price target on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Maxim Group set a $84.00 price target on shares of Gilead Sciences and gave the stock a buy rating in a research note on Tuesday, February 5th. Raymond James set a $90.00 price target on shares of Gilead Sciences and gave the stock a buy rating in a research note on Tuesday, February 5th. Citigroup reiterated a buy rating and set a $100.00 price target on shares of Gilead Sciences in a research note on Tuesday, February 5th. Mizuho restated a buy rating and issued a $88.00 target price on shares of Gilead Sciences in a research note on Tuesday, February 26th. Finally, Oppenheimer set a $85.00 target price on shares of Gilead Sciences and gave the stock a buy rating in a research note on Tuesday, March 19th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $79.54.

Shares of NASDAQ:GILD traded down $0.03 during trading hours on Tuesday, reaching $63.34. The stock had a trading volume of 3,798,867 shares, compared to its average volume of 7,227,061. Gilead Sciences has a 1 year low of $60.32 and a 1 year high of $79.61. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. The company has a market cap of $81.56 billion, a PE ratio of 10.30, a P/E/G ratio of 0.78 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating the Zacks’ consensus estimate of $1.53 by $0.23. The firm had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company’s revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm posted $1.48 EPS. As a group, equities research analysts expect that Gilead Sciences will post 6.6 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a $0.63 dividend. The ex-dividend date is Thursday, June 13th. This represents a $2.52 annualized dividend and a dividend yield of 3.98%. Gilead Sciences’s dividend payout ratio is presently 40.98%.

In related news, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the completion of the sale, the director now owns 34,669 shares in the company, valued at $2,270,126.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Francis Cogan sold 2,868 shares of Gilead Sciences stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $64.89, for a total transaction of $186,104.52. Following the completion of the sale, the director now owns 57,728 shares of the company’s stock, valued at approximately $3,745,969.92. The disclosure for this sale can be found here. Insiders sold 28,602 shares of company stock worth $1,863,445 over the last three months. Corporate insiders own 0.20% of the company’s stock.

Several large investors have recently modified their holdings of GILD. Muhlenkamp & Co. Inc. bought a new position in shares of Gilead Sciences during the first quarter worth about $8,642,000. Rehmann Capital Advisory Group grew its position in shares of Gilead Sciences by 1.7% during the first quarter. Rehmann Capital Advisory Group now owns 11,906 shares of the biopharmaceutical company’s stock worth $774,000 after acquiring an additional 203 shares during the last quarter. Diversified Trust Co grew its position in shares of Gilead Sciences by 4.5% during the first quarter. Diversified Trust Co now owns 24,165 shares of the biopharmaceutical company’s stock worth $1,571,000 after acquiring an additional 1,031 shares during the last quarter. Accident Compensation Corp grew its position in shares of Gilead Sciences by 13.6% during the first quarter. Accident Compensation Corp now owns 101,218 shares of the biopharmaceutical company’s stock worth $6,580,000 after acquiring an additional 12,100 shares during the last quarter. Finally, GYL Financial Synergies LLC bought a new position in shares of Gilead Sciences during the first quarter worth about $239,000. Institutional investors and hedge funds own 78.79% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: Green Investing

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.